Efficacité et sécurité des thérapies ciblées dans le syndrome VEXAS : étude rétrospective du FRENVEX. Hadjadj J, et al. Ann Rheum Dis. 2024. PMID: 38777378.
Diversité fonctionnelle des mutants gain-de-fonction de NLRP3 associés à l'inflammation CAPS. Cosson C, et al. J Exp Med. 2024. PMID: 38530241.
Syndrome ROSAH : arthrite débutant dans l'enfance, déformations des mains, uvéite et splénomégalie. Lequain H, et al. Lancet Rheumatol. 2023. PMID: 38251500.
Infections graves chez les patients atteints du syndrome VEXAS : données du registre français VEXAS. de Valence B, et al. Ann Rheum Dis. 2024. PMID: 38071510.
Diagnostic étiologique de l'uvéite : contribution de l'examen clinique extra-ophtalmologique. Jacquot R, et al. Ocul Immunol Inflamm. 2023. PMID: 37948510.
VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view. Heiblig M, Patel B, Jamilloux Y. Best Pract Res Clin Rheumatol. 2023. PMID: 37652853.
H syndrome treated with Tocilizumab: two case reports and literature review. Jacquot R, Jouret M, Valentin MG, et al. Front Immunol. 2023. PMID: 37638031.
Gut microbiota alterations are associated with phenotype and genotype in familial Mediterranean fever. Delplanque M, et al. Rheumatology (Oxford). 2024. PMID: 37402619.
VEXAS: is it time to reshape the nosology of clonal hematopoiesis? Sujobert P, Largeaud L, et al. Expert Rev Hematol. 2023. PMID: 37119011.
Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome. Faurel A, et al. Hemasphere. 2023. PMID: 36999004.
Mutations in the B30.2 and the central helical scaffold domains of pyrin differentially affect inflammasome activation. Chirita D, et al. Cell Death Dis. 2023. PMID: 36966139.
Mortality and Associated Causes in Hemophagocytic Lymphohistiocytosis: A Multiple-Cause-of-Death Analysis in France. La Marle S, et al. J Clin Med. 2023. PMID: 36836229.
Quantitative Assessment of Vacuolization of Myeloid Precursors in VEXAS Syndrome. Rabut A, et al. Hemasphere. 2023. PMID: 36751512.
VEXAS: where do we stand 2 years later? Sujobert P, et al. Curr Opin Hematol. 2023. PMID: 36728604.
H syndrome mimicking Erdheim Chester disease: new entity and therapeutic perspectives. Lequain H, et al. Haematologica. 2023. PMID: 36727401.
The course of non-infectious uveitis in pregnancy: a retrospective study of 79 pregnancies. Giorgiutti S, et al. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36565331.
The Spectrum of Still's Disease: A Comparative Analysis of Phenotypic Forms in a Cohort of 238 Patients. Neau PA, et al. J Clin Med. 2022. PMID: 36431180.
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases. Zakine È, et al. J Am Acad Dermatol. 2023. PMID: 36343774.
Diagnosing Hemophagocytic Lymphohistiocytosis with Machine Learning: A Proof of Concept. El Jammal T, et al. J Clin Med. 2022. PMID: 36294539.
Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome. Borie R, et al. Chest. 2023. PMID: 36272567.
Anakinra for the Treatment of Hemophagocytic Lymphohistiocytosis: 21 Cases. Baverez C, et al. J Clin Med. 2022. PMID: 36233667.
Management of Non-Infectious Uveitis, a Selection of Topical Items Updating. Sève P, et al. J Clin Med. 2022. PMID: 36233426.
Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism. Magnotti F, et al. Cell Rep. 2022. PMID: 36223753.
Quantification of canakinumab in human plasma by liquid chromatography-high resolution mass spectrometry. Millet A, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2022. PMID: 36179539.
Extreme Hyperferritinemia: Causes and Prognosis. Fauter M, et al. J Clin Med. 2022. PMID: 36143085.
Evaluation of Glycosylated Ferritin in Adult-Onset Still's Disease and Differential Diagnoses. Guerber A, et al. J Clin Med. 2022. PMID: 36078942.
Functional Assessment of Disease-Associated Pyrin Variants. Chirita D, et al. Methods Mol Biol. 2022. PMID: 35759198.
Murine typhus complicated by sHLH mimicking adult-onset Still's disease. Jacquot R, et al. Rev Med Interne. 2022. PMID: 35697578.
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Heiblig M, et al. Blood. 2022. PMID: 35609174.
Safety of canakinumab during pregnancy: seven new cases. Weber E, et al. Rheumatology (Oxford). 2022. PMID: 35325056.
Adult-onset Kawasaki-like disease as a paraneoplastic syndrome. Lequain H, et al. Rheumatology (Oxford). 2022. PMID: 35302598.
Mortality associated with Behçet's disease in France assessed by multiple-cause-of-death analysis. David E, et al. Clin Rheumatol. 2022. PMID: 35091777.
Detection and Prediction of Macrophage Activation Syndrome in Still's Disease. Javaux C, et al. J Clin Med. 2021. PMID: 35011947.
Inflammation of Unknown Origin: Evaluation and Prognosis of 57 Cases. Béra S, et al. J Clin Med. 2021. PMID: 35011773.
Diagnostic value of lumbar puncture for the etiological assessment of uveitis: a retrospective cohort of 188 patients. Bernier R, et al. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 34988612.
Still's Disease Mortality Trends in France, 1979-2016: A Multiple-Cause-of-Death Study. Borciuch C, et al. J Clin Med. 2021. PMID: 34640563.
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Georgin-Lavialle S, et al. Br J Dermatol. 2022. PMID: 34632574.
Development and Validation of a Bayesian Network for Supporting the Etiological Diagnosis of Uveitis. Jamilloux Y, et al. J Clin Med. 2021. PMID: 34362175.
Cardiovascular outcome in adult-onset Kawasaki disease. Peter E, et al. Autoimmun Rev. 2021. PMID: 34237418.
Characteristics and Clinical Value of 18F-FDG PET/CT in the Management of Adult-Onset Still's Disease: 35 Cases. Brisset J, et al. J Clin Med. 2021. PMID: 34199846.
ALPK1 Gene Mutations Drive Autoinflammation with Ectodermal Dysplasia and Progressive Vision Loss. Jamilloux Y, et al. J Clin Immunol. 2021. PMID: 34159509.
VEXAS syndrome in a woman. Barba T, et al. Rheumatology (Oxford). 2021. PMID: 33930131.
Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study. Sejournet L, et al. Br J Ophthalmol. 2022. PMID: 33875451.
Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients. Chirpaz NM, et al. Ocul Immunol Inflamm. 2022. PMID: 33826481.
Therapeutic options in VEXAS syndrome: insights from a retrospective series. Bourbon E, et al. Blood. 2021. PMID: 33619558.
Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. Vieira M, et al. Front Immunol. 2021. PMID: 33613571.
LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages. Omarjee O, et al. J Exp Med. 2021. PMID: 33606008.
Uveitis as an Open Window to Systemic Inflammatory Diseases. El Jammal T, et al. J Clin Med. 2021. PMID: 33466638.
Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor. Magnotti F, et al. Ann Rheum Dis. 2021. PMID: 33037005.
Low glycosylated ferritin is a sensitive biomarker of severe COVID-19. Fauter M, et al. Cell Mol Immunol. 2020. PMID: 32917980.
Diagnostic value of lymphopaenia and elevated serum ACE in patients with uveitis. Cotte P, et al. Br J Ophthalmol. 2021. PMID: 32917626.
Intravenous anakinra for cytokine storm syndromes. Jamilloux Y, et al. Lancet Rheumatol. 2020. PMID: 32838314.
Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis). Bertrand PJ, et al. Br J Ophthalmol. 2021. PMID: 32709757.
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Jamilloux Y, et al. Autoimmun Rev. 2020. PMID: 32376392.
Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). de Parisot A, et al. PLoS One. 2020. PMID: 32059021.
Complications de la maladie de Still de l’adulte [Adult-onset Still's disease complications]. Fauter M, et al. Rev Med Interne. 2020. PMID: 31924392.
Comment on: Improvement of MEFV gene variants classification to aid treatment decision making in familial Mediterranean fever. Jamilloux Y, Magnotti F. Rheumatology (Oxford). 2020. PMID: 31808527.
Anakinra in children and adults with Still's disease. Vastert SJ, et al. Rheumatology (Oxford). 2019. PMID: 31769856.
Les inhibiteurs de JAK : perspectives pour la médecine interne [JAK inhibitors: Perspectives in internal medicine]. El Jammal T, et al. Rev Med Interne. 2019. PMID: 31699450.
Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients. Magnotti F, et al. EMBO Mol Med. 2019. PMID: 31589380.
Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum. El Jammal T, et al. Joint Bone Spine. 2020. PMID: 31521793.
JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Jamilloux Y, et al. Autoimmun Rev. 2019. PMID: 31520803.
Uveitis: Autoimmunity… and beyond. Bertrand PJ, et al. Autoimmun Rev. 2019. PMID: 31323361.
Clinical and etiologic characteristics of de novo uveitis in patients aged 60 ans and above: experience of a French tertiary center. Grumet P, et al. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31312906.
Le temps est venu de réconcilier l’arthrite juvénile idiopathique systémique et la maladie de Still de l’adulte [It is time to reconcile systemic juvenile idiopathic arthritis and adult-onset Still's disease]. Jamilloux Y, et al. Rev Med Interne. 2019. PMID: 31221454.
BTNL2 gene polymorphism and sarcoid uveitis. Chaperon M, et al. Br J Ophthalmol. 2019. PMID: 30872286.
Successful treatment with anakinra of an HIV-associated immune reconstitution inflammatory syndrome mimicking adult-onset Still's disease. Bottlaender L, et al. Rheumatology (Oxford). 2019. PMID: 30239973.
Uveitis of Unknown Etiology: Clinical and Outcome features. A Retrospective Analysis of 355 Patients. Richard Colmant G, et al. Ocul Immunol Inflamm. 2019. PMID: 30234412.
Re: Dick et al.: Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Jamilloux Y, et al. Ophthalmology. 2018. PMID: 30032797.
A proximity-dependent biotinylation (BioID) approach flags the p62/sequestosome-1 protein as a caspase-1 substrate. Jamilloux Y, et al. J Biol Chem. 2018. PMID: 29929983.
The pyrin inflammasome: from sensing RhoA GTPases-inhibiting toxins to triggering autoinflammatory syndromes. Jamilloux Y, et al. Pathog Dis. 2018. PMID: 29718184.
Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological diagnosis). Grumet P, et al. Autoimmun Rev. 2018. PMID: 29427823.
Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Jamilloux Y, et al. Rheumatology (Oxford). 2018. PMID: 29040788.
Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review. Jamilloux Y, et al. Clin Rev Allergy Immunol. 2018. PMID: 28578473.
Péricardite récidivante : quoi de neuf en 2017 ? Jamilloux Y, et al. Rev Med Interne. 2017. PMID: 28283214.
Interleukine-1, inflammasome et maladies auto-inflammatoires. Jamilloux Y, et al. Rev Med Interne. 2018. PMID: 27639913.
Parenchymal lung involvement in adult-onset Still disease: A STROBE-compliant case series and literature review. Gerfaud-Valentin M, et al. Medicine (Baltimore). 2016. PMID: 27472698.
AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity. Di Micco A, et al. Proc Natl Acad Sci U S A. 2016. PMID: 27462105.
Cell-Free Assay for Inflammasome Activation. Jamilloux Y, et al. Methods Mol Biol. 2016. PMID: 27221492.
Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study. Barba T, et al. Medicine (Baltimore). 2015. PMID: 26705219.
Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases. Picard C, et al. Autoimmun Rev. 2015. PMID: 26269221.
Uveitis in adults: What do rheumatologists need to know? Sève P, et al. Joint Bone Spine. 2015. PMID: 26184541.
Adherence to online monitoring of patient-reported outcomes by patients with chronic inflammatory diseases: a feasibility study. Jamilloux Y, et al. Lupus. 2015. PMID: 25966927.
Treatment of adult-onset Still's disease: a review. Jamilloux Y, et al. Ther Clin Risk Manag. 2014. PMID: 25653531.
Données actualisées sur la physiopathologie, les phénotypes et les traitements de la maladie de Still de l'adulte. Gerfaud-Valentin M, et al. Rev Med Interne. 2015. PMID: 25466605.
Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Jamilloux Y, et al. Immunol Res. 2015. PMID: 25388963.
Les inflammasomes et les maladies humaines. Jamilloux Y, et al. Rev Med Interne. 2014. PMID: 24907108.
Adult-onset Still's disease. Gerfaud-Valentin M, et al. Autoimmun Rev. 2014. PMID: 24657513.
Les inflammasomes - Plates-formes de l'immunité innée. Jamilloux Y, et al. Med Sci (Paris). 2013. PMID: 24280500.
Caspase-1 activity affects AIM2 speck formation/stability through a negative feedback loop. Juruj C, et al. Front Cell Infect Microbiol. 2013. PMID: 23630667.
Inflammasome activation restricts Legionella pneumophila replication in primary microglial cells through flagellin detection. Jamilloux Y, et al. Glia. 2013. PMID: 23355222.
Adult-onset Still's disease. Gerfaud-Valentin M, et al. Autoimmun Rev. 2014. PMID: 24657513.
Myocarditis in adult-onset still disease. Gerfaud-Valentin M, et al. Medicine (Baltimore). 2014. PMID: 25398063.
Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. Gerfaud-Valentin M, et al. Rheumatol Int. 2014. PMID: 23624554.
